Cell-based assays, if appropriately designed, can be used to rapidly identify molecular mechanisms of human disease and develop novel therapeutics. In the last 20 years...
PK/PD Modeling of Adinazolam
Develop a model for prediction of the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of Adinazolam from IV, immediate release oral, and controlled release oral formulations.
Influence Of Estimation Of Inter-Occasion Variability On Detection Of Time-Varying Covariates
To explore the influence of the estimation of inter-occasion variability (IOV) on the ability to detect time-varying covariates influencing PK parameters from a population PK (PPK) analysis using NONMEM.
Plasma Pharmacokinetic (PK) Profile of Two Consecutive Doses of Ferumoxytol in Healthy Subjects
Ferumoxytol is a carbohydrate-coated superparamagnetic iron oxide nanoparticle being evaluated for safety and efficacy in two distinct areas of medical need.
Prediction of Log P with Property‐Based Methods
This first systematic overview for more than a decade is tailor-made for the medicinal chemist.
Simulations Plus Releases Major Upgrade To GastroPlus(™) Software
Version 5.3 Further Enhances Industry's Gold Standard Product
Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs
The aim of this study was to evaluate different physiologically based modeling strategies for the prediction of human pharmacokinetics.
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients
To characterise the population pharmacokinetics of trabectedin (ET-743, Yondelis(R)) in cancer patients.
Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma
To characterize the population pharmacokinetics (PK) of (R)- and (S)-albuterol in pediatric asthmatics using a model that supports a sparse blood sampling strategy.
Experienced Formulation Scientist Becomes Director of Life Sciences
Dr. John Crison Joins Simulations Plus
Simulations Plus and Enslein Research Sign Agreement
Prediction of Metabolism from Important Group of Enzymes to be Added to ADMET Predictor™
Simulations Plus Reports Fourth Quarter and Fiscal Year 2007 Preliminary Revenues
Another New Record Set for Quarterly and Annual Revenues
U.S. National Institutes of Health Licenses Simulations Plus’ ClassPharmer™ Software
Another Government Agency Licenses Key Software Product
U.S. FDA Expands Simulations Plus Software Licenses
GastroPlus and DDDPlus Licenses Added
Targeting Plague Virulence Factors: A Combined Machine Learning Method and Multiple Conformational Virtual Screening for the Discovery of Yersinia Protein Kinase A Inhibitors
Yersinia spp. is currently an antibiotic resistance concern and a re-emerging disease.
Pharmacometrics and the transition to model-based development
As the transition to model-based drug development continues, pharmacometric analysis will have an increasingly important role across the entire life cycle of drug discovery...
Simulations Plus Releases Unique Dna Mutation Predictor
New Software Screening Tool Helps Pharmaceutical Chemists Predict Drug-Caused DNA Mutations
Simulations Plus Releases Admet Predictor™ Version 2.3
Predictive Accuracy and User Convenience of Best-in-Class Software Now Further Improved